Led by a team of internationally experienced drug hunters with ADC and drug development experience and outstanding track records of innovation and commercial success.
Senior Leadership Team
Mohit Rawat, MBA
Chief Executive Officer
Mohit Rawat, MBA
Chief Executive Officer
Mohit joined Myricx Bio in September 2025.
He brings over two decades of experience as a biopharma leader and has a track record of driving innovations in drug discovery to commercial and transactional success.
Most recently, Mohit was President and Chief Business Officer (CBO) at Fusion Pharmaceuticals where he played a pivotal role in transforming the company which was acquired by AstraZeneca for $2.4 billion in 2024.
Previously, he held senior leadership roles at Novartis and Abbvie, where he built his expertise in novel drug development, commercial execution, business development and corporate strategy. Mohit has led, developed and launched multiple specialty products in oncology and other therapeutic areas, led multi-billion-dollar topline specialty businesses, and worked across M&A and business development and licensing transactions exceeding $5 billion in value. Earlier in his career Mohit was at McKinsey and Company, where he was a leader in the biopharmaceutical practice.
Mohit holds an MBA from Harvard Business School and MS in Chemical Engineering from the Massachusetts Institute of Technology (MIT).
Robin Carr, PhD
Chief Technology Officer
Robin Carr, PhD
Chief Technology Officer
Robin joined Myricx in November 2019 as Chief Development Officer and became Chief Executive Officer in August 2022, he transitioned to the role of Chief Technology Officer in September 2025.
Robin joined Myricx from GSK, where he held several research Exec roles (2007-2019), his final role was SVP Drug Design and Selection, with global responsibility for small molecule and biopharm discovery platforms. Robin served as a member of GSK’s Discovery Investment Board, Technology Investment Board and co-chaired the target selection committee.
Prior to GSK, Robin was VP of drug discovery at Astex Therapeutics (1999-2007), with responsibility for internal and partnered drug discovery programs.
Robin holds a chemistry degree from Imperial College London (1981) and completed his PhD studies in total synthesis at Northwestern University, Chicago (1984). Robin then returned to the UK to start his industrial research career at ICI agrochemicals before joining Glaxo in 1989 to focus on drug discovery.
Robin has co-authored and published 50 papers and patents and contributed to numerous discovery programs (cancer and respiratory) that have progressed into the clinic and two of which went on to become launched drugs.
Robin has a long-standing interest in novel drug discovery platforms that have the potential to reduce attrition rates and therefore increase R&D productivity.
Francesca Zammarchi, PhD
Chief Scientific Officer
Francesca Zammarchi, PhD
Chief Scientific Officer
Francesca joined Myricx in October 2023.
Francesca brings over two decades of cancer biology research experience, including developing Antibody-Drug Conjugates (ADCs), gained while working in the biopharma industry and in academia.
Most recently she was Head of Preclinical Pharmacology at ADC Therapeutics SA (NYSE: ADCT). During her 10 years at ADC Therapeutics, she worked as a cancer biologist actively involved in the discovery and evaluation of new projects for the company’s portfolio. She was also responsible for preclinical pharmacology studies and progressed multiple ADCs with novel payloads through IND to BLA.
In her earlier academic career, she was a Research Associate at Memorial Sloan-Kettering Cancer Centre, and Research Associate and Visiting Fellow at Mount Sinai School of Medicine.
Francesca gained her Ph.D. in experimental and molecular oncology and her B.Sc. in molecular biology from the University of Pisa, Italy.
Julie Mead
Chief Operating Officer /
Chief Financial Officer
Julie Mead
Chief Operating Officer / Chief Financial Officer
Julie joined Myricx in December 2023.
Julie has over 15 years experience as a pharma and biotech equity analyst for global investment banks, including Goldman Sachs and HSBC. She has covered some of the largest listed companies in European pharma and led the launch of HSBC's European biotech industry coverage.
She has also built operational capabilities and new client segments within global industry consultancies and financial services.
Julie has a Masters in Molecular and Cellular Biochemistry from Oxford University and investment examinations from the Securities Institute and CAIA.
Jesper Valbjørn
Senior Vice President CMC
Jesper Valbjørn
Senior Vice President CMC
Jesper joined Myricx Bio in February 2025.
Jesper has nearly 30 years of expertise in Antibody-Drug Conjugates (ADCs), antibody product development, and manufacturing, spanning from pre-IND stages to commercial production.
Most recently he was SVP Head of CMC at Genmab A/S. During his 19 years at Genmab he was involved in the development of monoclonal antibody products, ADC products and bispecific antibody products.
At Genmab he played a pivotal role in multiple programs including the early development of Kesimpta® and Darzalex®, the development and approval of TivDak® an ADC marketed for treatment of cervical cancer and the development and approval of Epkinky®/Tepkinly® a bispecific antibody for the treatment of certain lymphomas (DLBC and FL).
Prior to Genmab Jesper held research and leadership positions at Lundbeck A/S, Statens Serum Institut and Novo Nordisk. Jesper holds an M.Sc. from the Royal Veterinary and Agricultural University Copenhagen.
Steen Lisby, MD, DMSc.
Chief Medical Officer
Steen Lisby, MD, DMSc.
Chief Medical Officer
Steen joined Myricx Bio in February 2025.
He has 28 years of experience gained from first working in the clinic and then pharma industry, giving him excellent insights about linking research with clinical development.
Over his career Steen has championed the development of monoclonal antibodies, antibody-drug-conjugates (ADCs) , bispecific antibodies as well as radioimmunotherapy within the fields of oncology, haematology, and autoimmune diseases. He has significant experience working with cross functional teams and developing predominantly early phase I/II therapeutics.
Most recently Steen was SVP CMO/CSO, Global Head of Translational Medicine at Y-mAbs Therapeutics, Denmark where he was responsible for several successful regulatory (IND) submission. Also, during his career, he has led the early development of four therapeutic assets that all received regulatory approval.
Previously he has also held senior medical roles at Genmab, Denmark including VP, Head of Medical Department, and he has worked at GSK, UK, where he was Director Biopharm.
Steen has co-authored over 50 scientific papers published in peer reviewed journals and is an author on over 20 patent applications.
Steen holds a Doctor of Medical Science (DMSc) and MD from the University of Copenhagen.
Co-founders
Andrew Bell, PhD
Co-founder and Chemistry Consultant
Andrew Bell, PhD
Co-founder and Chemistry Consultant
As a one of the world’s leading medicinal chemists, Andy is a co-inventor of Sildenafil and a contributor to the development of Voriconazole; together these medicines have generated sales in excess of $40 billion.
In addition to his role as a chemistry consultant at Myricx, Andy is Chief Research Officer at Exscientia.
He had a 30 year career in research at Pfizer, followed by seven years as a Research Fellow at Imperial College London, where he led the medicinal chemistry effort on a project to discover novel inhibitors of N-myristoyltransferase for the treatment of parasitic infections.
Andy was awarded the Technical Achievement Award in Organic Chemistry by the American Chemical Society in recognition for his contributions to medicinal chemistry.
Andy obtained a PhD in Medicinal and Pharmaceutical Chemistry from Imperial College London and a BA from the University of York.
Ed Tate, PhD
Co-founder and Chairman of the Scientific Advisory Board
Ed Tate, PhD
Co-founder and Chairman of the Scientific Advisory Board
With over 20 years of research at the interface between organic chemistry, the life sciences and medicine, Ed is the world leader in the biology and chemistry of N-myristoyltransferase (NMT), a novel and emerging drug target for a wide range of oncology and viral indications.
Ed was previously the CSO at Myricx and is now Chairman of the Scientific Advisory Board. He is the GSK Chair of Chemical Biology at Imperial College London and a Satellite Group Leader at the Francis Crick Institute.
His academic research programme in drug target discovery and validation focuses on protein post-translational modifications. Working in close collaboration with a worldwide network of scientists, his research team was the first to validate N-myristoyltransferase (NMT) as a pharmacological target in malaria and antiviral indications and his team has developed the most potent and efficacious inhibitors of human NMT reported to date.
He established an independent group at Imperial College in 2006 and was promoted to full Professor in 2014. Ed has raised > £20 million in research funding to date, and his group of over 50 scientists and researchers is supported by grants and awards from the UK government, industry, the European Union, Cancer Research UK, and charitable foundations.
Ed is the recipient of multiple prizes recognising his work in chemical biology and drug discovery including the the RSC Corday-Morgan Prize, Sir David Cooksey Prize in Translation, the CRUK Programme Foundation Award, the RSC Norman Heatley Award, the Medimmune Protein and Peptide Science Award, the Wain Medal, the BBSRC David Phillips Fellowship, and the 1851 Research Fellowship.
He is a Fellow of the Royal Society of Chemistry (FRSC) and of Biology (FRSB) and sits on several Scientific Advisory Boards in the UK and internationally.
Earlier in in his career Ed was a postdoctoral fellow at the Ecole Polytechnique and the Institut Pasteur in Paris, France.
Ed obtained his PhD in Organic Chemistry from the University of Cambridge, UK.
Roberto Solari, PhD
Co-founder, founding CEO and Biology Consultant
Roberto Solari, PhD
Co-founder, founding CEO and Biology Consultant
A cell biologist and biotech entrepreneur, Roberto brings to Myricx unique perspectives that align science and business with the operations required for start-ups.
Roberto was previously Head of Biology and Chairman at Myricx having served as Myricx’s CEO from its foundation until August 2022. He is a member of the Translation Advisory Board of the Francis Crick Institute.
Previously, he was Vice President and Head of Biology in the respiratory therapy area at GlaxoSmithKline, UK. He spent four years as CEO of MRC Technology (now LifeArc), the technology transfer arm of the MRC, where he helped the creation of spinout companies including Heptares. Before this he was an Advisor to Apax Partners, London and an Entrepreneur in Residence with Abingworth Management where he helped start a number of companies including Astex Pharmaceuticals.
He has served on the board of several biotechnology companies and is currently a Venture Partner with Brandon Capital Partners.
As an academic researcher, his earlier career included positions at the University of Lausanne, Switzerland and the University of Liverpool UK.
Roberto obtained a BSc and a PhD from the University of Nottingham, UK.
NMTi Scientific Advisers
Francesco Falciani, PhD
Bioinformatics consultant
Francesco Falciani, PhD
Bioinformatics consultant
With over 30 years of experience working in both academia and industry, Francesco is a specialist in developing novel computational approaches in systems biology and the application of these techniques to complex biological systems.
Francesco holds an Honorary Professorship in integrative Systems Biology at the University of Liverpool where until 2021 he served as a Director of the University’s Computational Biology facility.
Before establishing his career in academia, Francesco worked at GlaxoWellcome as Bioinformatics Group Leader and was Head of Target Discovery at Lorantis Ltd.
Francesco was a pioneer in the development and application of computational methods for inferring the structure of gene regulatory networks from observational data. He has led systems biology projects in the areas of toxicology, environmental toxicology, and biomedicine.
Francesco has a degree in Molecular Biology from the University of Florence, Italy and worked as a postdoctoral research fellow in the Genetics Department at the University Cambridge, UK.
Mark Graham, BSc, PhD, FABT
Consultant Toxicologist
Mark Graham, BSc, PhD, FABT
Consultant Toxicologist
Mark spent 28 years in the Pharmaceutical Industry working in Preclinical Drug Discovery, the last 19 years of which were in AstraZeneca where he had a number of senior scientific leadership roles in Global Safety Assessment.
For the last 12 years Mark has worked as an independent consultant providing expert preclinical safety support to Biotech companies working in most therapeutic areas (Oncology, Inflammation, Gastrointestinal and Neuroscience) at all stages of drug discovery and development. In addition to founding MG Toxicology Consulting Ltd, Mark founded 448 Therapeutics Ltd (which transitioned into JAGUAHR Therapeutics), a virtual immune-oncology drug discovery company, and successfully delivered a novel small molecule immuno-oncology candidate drug in 2023.
As well as a career in Pharmaceutical R&D, Mark maintained activity in research via collaborations with several UK Universities involving the supervision of PhD students and Post-Doctoral scientists resulting in many peer-reviewed publications. Mark was also a visiting Professor (Toxicology) at the University of Surrey and is currently a visiting Professor at the University of Birmingham.
Mark served for 9 years as a member of the Committee on Toxicology (COT), advising the UK Government on all aspects of chemical toxicology. In 2008, Mark was awarded a Fellowship of the British Toxicology Society for his contributions to the science of Toxicology.
ADC Scientific Advisers
John Lambert, PhD
Independent Biotechnology Consultant, Former EVP Research and CSO, ImmunoGen Inc
John Lambert, PhD
Independent Biotechnology Consultant, Former EVP Research and CSO, ImmunoGen Inc
John is an experienced Independent Biotechnology Consultant with a track record of cancer drug development success. He is an expert in antibody-drug conjugates (ADCs).
John held a variety of leadership roles at ImmunoGen Inc. including most recently as Executive Vice President, Research and Chief Scientific Officer, where he played a pivotal role in translating the technology of ImmunoGen into ADC clinical development programmes. These efforts ultimately led to Genentech/Roche Kadcyla®, one of the first ADCs that was approved by the FDA for treating HER2+ breast cancer. He was also involved in supporting many additional ADC programmes that continue to be developed by ImmunoGen and its partners.
Prior to joining ImmunoGen, John served as Assistant Professor of Pathology at the Dana-Farber Cancer Institute of the Harvard Medical School. He completed his postdoctoral work at the University of California, Davis and Glasgow University, Scotland.
He is the author/co-author of more than 125 peer-reviewed scientific publications.
John is an elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and an Honorary Professor of Queen’s University, Belfast, Northern Ireland, UK.
John holds a Natural Science degree and a PhD in Biochemistry from University of Cambridge, UK .
Simon Chivers, PhD
Toxicology advisor, ex-head of Toxicology at ADC Therapeutics, and ex-Global Head of Safety Assessment at Novartis
Simon Chivers, PhD
Toxicology advisor, ex-head of Toxicology at ADC Therapeutics, and ex-Global Head of Safety Assessment at Novartis
Simon is co-director and consultant toxicologist, at Integrated Biologix GmbH. He has over 20 years’ experience in non-clinical drug development, with a focus on biological products across a wide range of modalities.
Simon has extensive expertise in ADC toxicology. He previously held the role of Head of Toxicology at ADC Therapeutics, where he was responsible for the non-clinical safety assessment of the company’s antibody-drug conjugates, non-antibody-drug conjugates and conjugate toxins, which resulted in multiple successful IND submissions and active clinical trials.
He has also held numerous industry leadership roles, including Global Head of Biologics Safety Assessment at the Novartis Institute of BioMedical Research and Senior Safety Assessment Expert at AstraZeneca / MedImmune, and Senior Toxicologist at Syngenta Biopharma.
He is an active member of the British Toxicology Society and British Pharmacological Society and serves as a Reviewer of articles for the Journal of Applied Toxicology. He actively supports relevant BioSafe committees including the Antibody Drug Conjugate group.
Simon has a PhD in Applied Pharmacology from Imperial College London and a BSc in Pharmacology from UCL.
Mike Sun, PhD
CMC Adviser, ex-SVP CMC at Seattle Genetics
Mike Sun PhD
CMC Adviser, ex-SVP CMC at Seattle Genetics
Mike is a Senior Antibody-Drug Conjugate (ADC) CMC consultant with almost 20 years of experience from pre-IND to commercial.
He has held leadership positions in development, manufacturing, and CMC strategy, including most recently as Senior Vice President, CMC at VelosBio Inc (acquired by Merck).
Previously he was VP, Manufacturing at Silverback Therapeutics (acquired by ARS Pharmaceuticals).
Earlier he was at Seattle Genetics, where he held roles as Senior Director and Head of Clinical Manufacturing, and Director and Head of Purification and Conjugation Process Development. At Seattle Genetics he played a pivotal part in the development of multiple ADC programmes, including as the CMC lead for ADCETRIS®, an ADC now marketed for certain CD30-expressing lymphomas.
Mike holds a PhD in Chemical Engineering from the University of California, Berkeley and a B.S in Chemical Engineering from the University of Washington.
